RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment
illi News/10268822

YANTAI, China, June 5, 2024 ~ At the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024, RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its latest innovations in the field of global cancer treatment. The company presented major research results on its proprietary antibody drug conjugates (ADCs) Disitamab Vedotin (RC48) and RC88.

The innovative drugs were featured in one Clinical Science Symposium, five Poster presentations, and ten online Abstracts at ASCO 2024. These presentations covered multiple cancer types including gastric and bladder cancer, and gynecological tumors. The studies included both monotherapy and combination therapies.

Dr. Jianmin Fang, CEO of RemeGen, expressed his honor at presenting the company's latest research findings on an internationally renowned stage such as ASCO Annual Meeting 2024. He stated that this not only demonstrates RemeGen's leading position in the field of antibody-drug conjugates in China but also proves their commitment to continuing research efforts to provide effective treatment options for patients worldwide.

More on illi News
One of the highlights of RemeGen's presentations was an oral presentation at a Clinical Science Symposium by Professor Song Li from Qilu Hospital of Shandong University. The presentation was based on a randomized, controlled (RCT) multicenter, single-arm, Phase II trial investigating the efficacy of RemeGen's disitamab vedotin (RC48) combined with toripalimab and the oral fluoropyrimidine S-1 in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.

In addition to this symposium, RemeGen also presented five posters at ASCO 2024. One of these posters, presented by Professor Sheng Xinan from Peking University Cancer Hospital, focused on the preliminary efficacy and safety results of RC48-C017, a Phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC). The interim results showed promising efficacy and a manageable safety profile in operable MIBC patients, supporting further investigation for disitamab vedotin plus toripalimab in this population.

More on illi News
Other poster presentations included a Phase II multi-center study on adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression, and a prospective, single-arm, single-center clinical study on disitamab vedotin combined with toripalimab in patients with advanced penile cancer who have progressed on treatment or are intolerant to cisplatin chemotherapy.

In addition to these presentations, RemeGen also had ten online abstracts accepted by ASCO. These abstracts reflected the results of their RC48 and RC88 drugs in bladder, breast, and GI cancers. This further demonstrates the company's prolific innovation in global cancer treatment.

RemeGen's participation at ASCO 2024 highlights their commitment to advancing cancer treatment options globally. With their innovative drugs and ongoing research efforts, they continue to make significant contributions to the field of oncology.
Filed Under: Business

Show All News | Report Violation


Latest on illi News